180 results about "Virus-like particle" patented technology

The present invention relates to a method for producing higher titers and / or a higher quality of recombinant viruses and / or less or reduced impurities in virus like particle (VLP) production in respective production processes in mammalian cell lines, the method comprising the step of supplementing a suitable mammalian cell line culture media with at least one intermediate substrate of the tricarboxylic acid (TCA) cycle and optionally supplementing the suitable mammalian cell line culture media with further additives and / or further adjusting the conditions of the mammalian cell line culture media. Furthermore, the present invention relates to the balanced suitable mammalian cell line culture media and the use of this balanced suitable mammalian cell line culture media for producing higher titers and / or a higher quality of recombinant viruses and / or less or reduced impurities in virus like particle (VLP) production in respective production processes for producing higher titers and / or quality of recombinant viruses.

The application discloses a reagent, a method and application of the reagent and the method for simultaneously detecting three common viruses in a fancy carp, and belongs to the technical field of fish quarantine. The application provides a reaction system and a detection method for simultaneously detecting three common viruses in a fancy carp, establishes a multiplex fluorescence PCR method, adopts a full-closed reaction, solves the problem that common PCR is prone to generating aerosols and causing false positive results of tests, has high detection sensitivity, can detect target genes with a copy number of 10 orders of magnitude at the minimum, is suitable for detecting a small amount of viruses carried in normal fancy carp or viruses in water quality environment, and can fully meet the requirements of customs quarantine prevention and control, has strong specificity, has no cross reaction to templates such as IHNV, RSIV and EHNV, and further provides a virus-like particle which can be used as a positive reference product in the multiplex system, is stable in state and beneficial to storage, can monitor an extraction process, and ensures that a test is established.

The present invention provides a fusion protein and an expression vector for enhancing the soluble expression of norovirus antigens. More specifically, it provides a combination of diverse genotypes of norovirus antigen proteins and RID mutations that, when norovirus antigens are used as target proteins, fold most efficiently during the formation of recombinant fusion proteins, improve the soluble expression yield of the produced fusion proteins, and enhance the assembly efficacy and homogeneity of norovirus VLPs. Furthermore, by utilizing mutational RIDs, the present invention provides a method for rapidly and in large quantities producing not only GII.4 but also other diverse genotypes of norovirus VLPs in E. coli, thereby enabling the development of VLP-based multivalent vaccines containing a wider range of genotypes.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

The invention discloses a virus-like particle coated with an aluminum-containing metal organic framework mineralization layer and application of the virus-like particle. In order to improve the VLPs vaccine stability and immune effect, the invention synthesizes a novel aluminum-containing metal organic framework (ZAM). The ZAM can mineralize the VLPs at a high level under a mild condition to form the VLPs-ZAM nano vaccine. Taking a foot and mouth disease virus (FMDV) virus-like particle (VLPs) vaccine as an example, a heat treatment test shows that ZAM mineralization significantly improves the heat stability of FMDVVLPs, and the effect is superior to that of Al (OH) 3 and ZIF-8. The FMDV VLPs-ZAM not only has the effect of promoting APCs to take in FMDVVLPs, but also can promote antigens to escape from lysosome to cytoplasm due to the pH responsiveness of the FMDV VLPs-ZAM. A mouse immune test shows that ZAM mineralization improves the specific immune response level and stability induced by FMDV VLPs. The invention provides a new technical means for improving the stability of the VLPs vaccine and the immune effect of the VLPs vaccine.

The present disclosure relates to virus-like particles (VLPs) comprising one or more antigens for use as vaccines. The present disclosure also relates to the use of the vaccine for the treatment of an SARS-CoV-2 infection or a coronavirus disease 2019 (COVID-19).

The application discloses nanobodies against E protein of chikungunya virus and application in virus detection, and the nanobodies against E protein of chikungunya virus include N055 and 10G4 antibodies, and both have high affinity and binding activity with antigens. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by the nanobodies of the N055 and 10G4 antibodies can efficiently detect E protein of chikungunya virus and virus-like particles, and the detection sensitivity can reach 49 pg / mL, and the antibody combination has wide application prospects in diagnosis and pathogen detection of chikungunya virus disease.

The invention discloses a GNRH-I-MS2 fusion protein, a castrated MS2 virus-like particle subunit vaccine and a preparation method of the castrated MS2 virus-like particle subunit vaccine.

The present invention provides: a culture medium composition which contains a pyruvate dehydrogenase kinase inhibitor and is used for promoting the production of a virus having a target gene mounted thereon when culturing a virus-producing cell into which the target gene has been introduced; a culture medium composition for promoting the production of a virus or a virus-like particle when culturing a cell that produces the virus or the virus-like particle; and the like.

The present disclosure relates to a composition comprising one or more ribonucleic acids (RNAs) encoding virus-like particle (VLP) forming elements of an influenza virus. The present disclosure further provides uses of the composition.

A vaccine for use in the prophylaxis and / or treatment of a diseaseThe present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

The invention belongs to the technical field of biological medicine and disease prevention and treatment, and particularly relates to an SSEA4 conjugated virus-like particle anti-cancer vaccine as well as a preparation method and application thereof. Specifically, according to the vaccine, an SSEA4 antigen is efficiently synthesized through a chemical enzyme method, then the SSEA4 antigen is covalently coupled with a virus-like particle (VLP), the SSEA4 antigen and the VLP are combined with a monophosphoryl lipid A adjuvant with high safety, an organism can be induced to generate strong and lasting SSEA4-resistant humoral immune response, the generated antibody can specifically recognize and kill SSEA4 positive tumor cells, and the SSEA4 positive tumor cells can be effectively killed. Meanwhile, good safety is shown in an animal model, a new solution is provided for immunotherapy of SSEA4 positive tumors, and therefore the SSEA4 positive tumor immunotherapy polypeptide has wide application prospects and market value.

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

The invention discloses a method for analyzing related impurities in a virus-like particle drug, which adopts a tandem chromatography system consisting of a large-aperture size exclusion chromatographic column A and a small-aperture composite chromatography chromatographic column B which are directly connected, the column B has a separation mechanism of volume exclusion and hydrophobic interaction, chromatographic signals are detected, and the related impurities in the virus-like particle drug are analyzed. Synchronous separation, identification and quantification of virus-like particle related components, capsid protein related components and free oligonucleotide related components are realized by analyzing the peak appearance sequence of each chromatographic peak and the absorption signal intensity ratio under different wavelengths. The method effectively solves the problem of co-elution of different types of impurities, especially capsid proteins and free oligonucleotides in a traditional chromatographic method, has the advantages of high separation degree, accurate quantification and good repeatability, and is suitable for process development and quality control of virus-like particle drugs.

The application discloses a virus-like particle vaccine freeze-drying protective agent and a preparation method thereof. The freeze-drying protective agent comprises A liquid and B liquid mixed in a volume ratio of 1:1 to 3:1; the A liquid comprises the following components with terminal concentrations: 0.01-0.5 mol / L base liquid I, 0.5-2 mmol / L base liquid II, 0.01-0.1% polysorbate 80, 5-20% sucrose and 1-5% trypsin; and the B liquid comprises the following components with terminal concentrations: 0.1-5% trehalose, 0.1-5% oligogalactose and 0.1-2% PEG6000. Through the compounding of the A liquid and the B liquid, the application can effectively enhance the immunization effect of the vaccine, prolong the storage time of the vaccine and keep the virus-like particle form intact.

The invention relates to an extracellular vesicle (EV), viral particle or virus like particle (VLP) comprising an RNA molecule attached to the internal surface of the EV membrane, to the viral particle or to the VLP membrane via a fusion protein comprising an EV membrane, viral particle or VLP protein or part thereof and an RNA-binding domain, wherein the RNA molecule comprises at least one stemloop, an siRNA sequence and a sequence that is recognized by the RNA-binding domain, and wherein the sequence that is recognized by the RNA-binding domain is bound by the RNA-binding domain, to encoding nucleic acid molecules and uses thereof.

This invention belongs to the field of bioengineering and virus-like particle (VLP) construction technology, specifically relating to an amino acid sequence with steric hindrance effect and its preparation method, the VP2 protein of recombinant porcine parvovirus and its nucleotide sequence, and the virus-like particles assembled from it. An amino acid sequence with steric hindrance effect, SEQ ID NO: 1, is provided. This invention provides an amino acid sequence with steric hindrance effect, which is fused to the N-terminus of the wild-type VP2 protein to obtain a modified VP2 protein. During the critical phase of the assembly of the modified VP2 protein into VLPs, SEQ ID NO: 1 at the N-terminus, due to its steric hindrance effect, pre-occupies and physically seals the 5-fold pores of the capsid, ensuring that the host background nucleic acid cannot enter the particle interior. Through protein structure modification, nucleic acid entry into the particle interior is physically blocked from the source, resulting in a pure antigen with extremely high hollowing rate.

The application discloses a nano antibody against Ebola virus VP40 protein and application thereof in Ebola virus detection, wherein the nano antibody against Ebola virus VP40 protein is a 3E07 antibody. The nano antibody against Ebola virus VP40 protein prepared by the application has the characteristics of high sensitivity and wide binding spectrum. A double antibody sandwich enzyme-linked immunosorbent assay method constructed by 3E07 and 3F06 antibodies can efficiently detect VP40 proteins and virus-like particles of various Ebola virus subtypes such as Zaire, Sudan and Beni, wherein the detection sensitivity of the Ebola virus VP40 protein of Zaire type can reach 0.039 ng / mL, and the antibody combination has a wide application prospect in the diagnosis and pathogen detection of Ebola virus disease.

The present invention relates to novel adenovirus capsid protein-based delivery vehicles. These are based on modified penton-based protomers that are assembled into VLPs. The exposed regions of the penton-based proteins can be modified to allow the VLP to specifically bind to any target and / or to include any desired peptide epitope. Additional cargo, e.g. drugs, proteins or nucleic acids, can be reversibly or irreversibly attached to the VLP via engineered protein fiber fragments.The present invention relates to such engineered penton-based protomers, engineered proteins comprising an adenovirus fiber N-terminal protein fragment that specifically binds to an adenovirus fiber protein binding cleft of a penton-based protomer, VLPs comprising the engineered penton-based protomers and optionally engineered proteins comprising an adenovirus fiber N-terminal protein fragment that specifically binds to an adenovirus fiber protein binding cleft of a penton-based protomer, nucleic acid encoding the engineered proteins, the VLPs as well as methods of producing the proteins and the VLPs.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 μg gB / pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients.

This invention relates to genetic engineering technology and aims to provide a method for preparing and applying bacteriophage capsid protein MS2-armored PRRSV antigen mRNA particles. The method includes: inserting the MS2 bacteriophage capsid protein gene and an mRNA expression cassette into a double multiple cloning site expression vector; transforming the recombinant expression plasmid into host bacteria; inducing expression to allow the MS2 capsid protein to express and self-assemble into virus-like particles; utilizing the specific recognition of the MS2 capsid protein on the packaging stem-loop structure, packaging the transcribed mRNA inside the virus-like particles to form MS2-armored PRRSV antigen mRNA particles; lysing the host bacteria, separating the supernatant, and enriching and purifying the particles. This invention significantly enhances the resistance of mRNA to nuclease degradation and improves formulation stability; it can increase the efficiency of mRNA entering antigen-presenting cells and enhance immunogenicity; it can be mass-produced with controllable processes and relatively low cost.

Relates to the technical field of biology, in particular to a castrated PapMV virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-PapMV recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-PapMV recombinant protein is high in antigen purity, good in safety and good in castration effect.

The present disclosure provides a method for producing recombinant adeno-associated virus particles having a ligand on surfaces thereof, virus-like particles, host cells, and virus virions (VP) having low hepatotoxicity, the method comprising: (A) a step for introducing, into host cells via gene delivery, a nucleic acid molecule containing a nucleotide sequence that encodes a desired protein, and one or more types of nucleic acid molecules containing a nucleotide sequence that allows the expression of VP1, VP2, VP3, and VP3 modified with the ligand upon gene delivery; and (B) a step for subjecting the host cells to conditions that allow the generation of the recombinant adeno-associated virus particles.

Relates to the technical field of biology, in particular to a castrated HBsAg virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-HBsAg recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-HBsAg recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

The application discloses a CMV virus-like particle for producing a VLP recombinant vaccine and a preparation method thereof, the CMV virus-like particle is obtained by cloning a C-terminal G4SLPETG modified plant virus cucumber mosaic virus CMV capsid gene into a prokaryotic expression vector to obtain a recombinant expression vector, the recombinant expression vector is transfected into E. coli BL21 (DE3), and expression is obtained through the recombinant E. coli BL21 (DE3); and the amino acid sequence of the C-terminal G4SLPETG modified CMV is SEQ ID NO. 1. Test proves that the recombinant strain constructed by the application is stable to expression of an exogenous protein. The recombinant protein expressed by the application is used for preparing a virus-like particle for antigen coupling, the coupling efficiency is high, the antigen purity is high, the safety is good, the virus-like particle is not pathogenic to mice and other animals, and the safety evaluation is easy.

The invention relates to a castrated TMV virus-like particle subunit vaccine and a preparation method thereof. The GnRH-I-TMV recombinant protein is high in purity and good in specificity. A vaccine prepared from the GnRH-I-TMV recombinant protein is high in antigen purity, good in safety and good in castration effect.